Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Japanese CTEPH Patients
NCT03809650Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of macitentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Actelion Pharmaceuticals Ltd. Started Jan 2019; status: terminated.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT03809650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809650.